The Rise of the Digital Asylum
The digital pill Abilify MyCite, which is now being introduced into the market, foretells of a future where such technology is used to monitor the behavior, location and "medication compliance" of a person 24 hours a day.
Your Pharmacist is Tattling On You!
A CVS pharmacy recently sent me a standardized form by fax with a dire warning about one of my patients. The form was called “MEDICATION NONADHERENCE THERAPY ADVISORY” and it said: “A review of your patient’s retail and mail prescription history indicates that the patient has not obtained his or her first refill.”
The Misuse of Collaboration and Therapy to Deter People From Discontinuing...
Gabriel Ivbijaro and Lucja Kolkiewicz produce five pages dedicated to improving adherence with psychiatric medication through collaborative care and the implementation of modified CBT. The use of the word ‘collaborative’ in this context is misleading.
Backing Away from Psychiatry
I believe now that fifteen years is more than a fair try. Fifteen years of getting treatment without returning to function is actually insanity. I should have given up after year two. Instead of trusting my intuition and insight, I pushed it down and down... until it finally fought its way back to the surface.
Our Day in Mental Health Court
For weeks I had been trying to get released from the psychiatric ward, and none of my arguments, compliance, or attempted air of normality had made an impression on the barely-visible ward psychiatrist. I had, I was told, made a very serious suicide attempt and this was a predictor of future attempts. They would let me know when they thought I was sufficiently remorseful and stabilized to be released.
FDA to Review “Digital Pill” to Monitor Patients on Antipsychotic
Last Thursday, the FDA agreed to review a “digital pill,” combining a sensor with the antipsychotic Abilify, in order to track patients’ compliance with drug treatment. Patients taking the tracker pill would also wear a patch, which would receive information and relay it to a mobile device, according to a brief report by BioPharmaDIVE.